| A Study of Cardiovascular Events iN Diabetes Plus | Active, not recruiting | P4 | University of Oxford |
| A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes | Recruiting | P4 | Per Løgstrup Poulsen |
| A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease | Completed | P3 | Novo Nordisk A/S |
| Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | Completed | P3 | Novo Nordisk A/S |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Recruiting | P3 | Novo Nordisk A/S |
| A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | Completed | P3 | Eli Lilly and Company |
| Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Completed | P3 | Eli Lilly and Company |
| Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | Active, not recruiting | P3 | Novo Nordisk A/S |
| A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Not yet recruiting | P3 | Amgen |
| A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec | Completed | P3 | Novo Nordisk A/S |
| Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial | Completed | P4 | Novo Nordisk A/S |
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Active, not recruiting | P3 | Eli Lilly and Company |
| Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight | Completed | P3 | Novo Nordisk A/S |
| A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus | Recruiting | P3 | AstraZeneca |
| A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus | Active, not recruiting | P3 | Gan & Lee Pharmaceuticals. |
| Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | Completed | P3 | Novo Nordisk A/S |
| A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE) | Completed | P4 | Novo Nordisk A/S |
| AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Not yet recruiting | P3 | Novo Nordisk A/S |
| A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) | Recruiting | P3 | The United Bio-Technology (Hengqin) Co., Ltd. |
| A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes | Completed | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. |
| Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus | Completed | P3 | Novo Nordisk A/S |
| Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes | Completed | P2 | Novo Nordisk A/S |
| Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3) | Completed | P3 | Novo Nordisk A/S |
| Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes | Completed | P2 | Novo Nordisk A/S |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo | Completed | P2 | Novo Nordisk A/S |
| A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes | Not yet recruiting | P3 | Guangdong Raynovent Biotech Co., Ltd |
| Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) | Completed | P3 | Novo Nordisk A/S |
| A Study of BGM0504 in Participants With Type 2 Diabetes | Active, not recruiting | P3 | BrightGene Bio-Medical Technology Co., Ltd. |
| A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes | Completed | P3 | Novo Nordisk A/S |
| A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus | Completed | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. | Completed | P3 | Novo Nordisk A/S |
| A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes | Completed | P2 | Novo Nordisk A/S |
| Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes | Not yet recruiting | P3 | Shandong New Time Pharmaceutical Co., LTD |
| Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes | Completed | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) | Completed | P3 | Novo Nordisk A/S |
| Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus | Not yet recruiting | P3 | Popular Medical College Hospital |
| Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes | Unknown | P3 | Chengdu Brilliant Pharmaceutical Co., Ltd. |